Portage Biotech (NASDAQ:ATON) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Portage Biotech (NASDAQ:ATON) in a research report report published on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $2.00 price objective on the stock.

Separately, Weiss Ratings started coverage on shares of Portage Biotech in a research report on Monday, January 26th. They set a “sell (e+)” rating for the company. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $2.00.

Portage Biotech Trading Down 2.4%

NASDAQ ATON opened at $0.40 on Tuesday. The firm has a market cap of $3.23 million, a PE ratio of -0.05 and a beta of 0.33. Portage Biotech has a 1-year low of $0.36 and a 1-year high of $15.82.

Portage Biotech (NASDAQ:ATON) last issued its quarterly earnings data on Wednesday, January 21st. The company reported ($4.13) EPS for the quarter.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.